US 12,371,498 · Application 16/959,425 · Granted Jul 29, 2025
US 12,371,498
Novel combination and use of antibodies
Estimated expiration
September 3, 2042
15y 364d remaining
- Could not fetch continuity data for application PCTEP2019050566: Resource not found (404)
Earliest effective filing
Jan 10, 2019
+ 20 years
Jan 10, 2039
PTA +1332d
Sep 3, 2042
No TD
—
Final
Sep 3, 2042
This calculation includes patent term adjustment (PTA) under 35 U.S.C. §154(b). Patent term extension (PTE) under 35 U.S.C. §156 (for FDA-regulated products) is not included.
Calculation details
Base term
- Filing date
- June 30, 2020
- Earliest effective filing
- January 10, 2019
- Issue date
- July 29, 2025
- PTA
- +1332 days
- Base expiry (before PTA)
- January 10, 2039
January 10, 2019 + 20 years = January 10, 2039 + 1332 PTA days = September 3, 2042
- National stage entry of application PCTEP2019050566, filed Jan 10, 2019
Terminal disclaimers
Patent term extension under 35 U.S.C. §156, which can apply to certain drug, biologic, animal drug and medical device patents, is not included in this calculation. How PTE is calculated
The prosecution record for your AI
Application 16/959,425 · US 12,371,498
You have the date. Your AI can have the file.
PatentReply compiles the prosecution history behind US 12,371,498: the claims as filed and as allowed, every Office Action and response, and the cited references, with each answer pointing back to the filed passage.
One public application a month is free. The first compile takes a few minutes.
Strategy and filing changes require your approval.
Permanent link
www.patentreply.ai/tools/patent-expiration/US12371498Data sourced from public USPTO records. This tool provides informational estimates and should not be relied upon as legal advice. Always verify patent expiration dates independently, especially where patent term extension, terminal disclaimers, or unusual continuity issues may apply.